Advertisement

Psychiatric Disorders in Women’s Health

  • Shambhavi Chandraiah
Chapter

Abstract

The global burden of psychiatric disorders is growing with major depression often being as debilitating as diabetes or coronary artery disease. Women often seek psychiatric care from their primary care provider or obstetrician/gynecologist. The most common psychiatric disorders seen in women include major depression, persistent depressive disorder, bipolar disorder as well as generalized anxiety disorder, panic disorder, social anxiety disorder, and post-traumatic stress disorder (PTSD). Most of these disorders are effectively treated with selective serotonin reuptake inhibitor (SSRI) or similar antidepressant/anxiolytic medications (+/−psychotherapy). However, bipolar disorder requires mood stabilizers.

Reproductively associated psychiatric disorders include premenstrual dysphoric disorder (PMDD), mood, anxiety, and psychotic disorders during pregnancy and postpartum, as well as perimenopausal depression and anxiety. Pregnancy and breastfeeding present unique situations where careful assessment and discussion of the impact of untreated psychiatric disorder versus the positive or potential negative side effects of the use of psychotropic medication on the fetus or infant is essential. Psychotherapy may be particularly useful as a primary treatment approach or as adjunct/alternative treatment when medication use may be problematic.

Keywords

Mood disorder Depression Bipolar disorder Anxiety Posttraumatic stress disorder Premenstrual dysphoric disorder Pregnancy Postpartum Lactation Perimenopause 

Notes

Acknowledgment

Thank you to Drs. Umesh Bhandari and Holly Kinget for their early contributions to this chapter.

References

  1. 1.
    Cassano P, Fava M. Depression and public health: an overview. J Psychosom Res. 2002;53(4):849–57.CrossRefGoogle Scholar
  2. 2.
    Sansone RA, Sansone LA. Psychiatric disorders: a global look at facts and figures. Psychiatry (Edgmont). 2010;7(12):16–9.Google Scholar
  3. 3.
    Murray CJ, Atkinson C, Bhalla K, Birbeck G, Burstein R, Chou D, Murray. The state of US health, 1990–2010: burden of diseases, injuries, and risk factors. JAMA. 2013;310(6):591–608.CrossRefGoogle Scholar
  4. 4.
    Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593–602.CrossRefGoogle Scholar
  5. 5.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Publishing; 2013.Google Scholar
  6. 6.
    Carlat DJ. The psychiatric review of symptoms: a screening tool for family physicians. Am Fam Physician. 1998;58(7):1617–24.PubMedGoogle Scholar
  7. 7.
    Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary care evaluation of mental disorders. Patient Health Questionnaire. JAMA. 1999;282(18):1737–44.CrossRefGoogle Scholar
  8. 8.
    Rush AJ. STAR*D: what have we learned? Am J Psychiatry. 2007;164(2):201–4.CrossRefGoogle Scholar
  9. 9.
    US Food & Drug Administration. FDA proposes new warnings about suicidal thinking, behavior in young adults who take antidepressant medications [press release]. Retrieved from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108905.htm. 2007.
  10. 10.
    Rupke SJ, Blecke D, Renfrow M. Cognitive therapy for depression. Am Fam Physician. 2006;73(1):83–6.PubMedGoogle Scholar
  11. 11.
    Lam RW, Levitt AJ, Levitan RD, Enns MW, Morehouse R, Michalak EE, Tam EM. The Can-SAD study: a randomized controlled trial of the effectiveness of light therapy and fluoxetine in patients with winter seasonal affective disorder. Am J Psychiatry. 2006;163(5):805–12.CrossRefGoogle Scholar
  12. 12.
    George MS, Nahas Z, Borckardt JJ, Anderson B, Foust MJ, Burns C, Short EB. Brain stimulation for the treatment of psychiatric disorders. Curr Opin Psychiatry. 2007;20(3):250–4. discussion 247–259CrossRefGoogle Scholar
  13. 13.
    Chandraiah S. STRAP E GooD. 2011.Google Scholar
  14. 14.
    Hirschfeld RM, Williams JB, Spitzer RL, Calabrese JR, Flynn L, Keck PE Jr, Zajecka J. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry. 2000;157(11):1873–5.CrossRefGoogle Scholar
  15. 15.
    Bowden CL, Perlis RH, Thase ME, Ketter TA, Ostacher MM, Calabrese JR, Sachs GS. Aims and results of the NIMH systematic treatment enhancement program for bipolar disorder (STEP-BD). CNS Neurosci Ther. 2012;18(3):243–9.CrossRefGoogle Scholar
  16. 16.
    Machado-Vieira R, Manji HK, Zarate CA Jr. The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord. 2009;11(Suppl 2):92–109.CrossRefGoogle Scholar
  17. 17.
    Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry. 1993;50(9):723–33.CrossRefGoogle Scholar
  18. 18.
    Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet. 2013;381(9878):1672–82.CrossRefGoogle Scholar
  19. 19.
    Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092–7.CrossRefGoogle Scholar
  20. 20.
    Durham RC. Treatment of generalized anxiety disorder. Psychiatry. 2004;3(4):30–4.CrossRefGoogle Scholar
  21. 21.
    Nemeroff CB, Bremner JD, Foa EB, Mayberg HS, North CS, Stein MB. Posttraumatic stress disorder: a state-of-the-science review. J Psychiatr Res. 2006;40(1):1–21.CrossRefGoogle Scholar
  22. 22.
    Berger W, Mendlowicz MV, Marques-Portella C, Kinrys G, Fontenelle LF, Marmar CR, Figueira I. Pharmacologic alternatives to antidepressants in posttraumatic stress disorder: a systematic review. Prog Neuro-Psychopharmacol Biol Psychiatry. 2009;33(2):169–80.CrossRefGoogle Scholar
  23. 23.
    Kung S, Espinel Z, Lapid MI. Treatment of nightmares with prazosin: a systematic review. Mayo Clin Proc. n.d.;87(9):890–900.CrossRefGoogle Scholar
  24. 24.
    Guina J, Rossetter SR, De Rhodes B, Nahhas RW, Welton RS. Benzodiazepines for PTSD: a systematic review and meta-analysis. J Psychiatr Pract. 2015;21(4):281–303.CrossRefGoogle Scholar
  25. 25.
    Otto MW, Deveney C. Cognitive-behavioral therapy and the treatment of panic disorder: efficacy and strategies. J Clin Psychiatry. 2005;66(Suppl 4):28–32.PubMedGoogle Scholar
  26. 26.
    Chandraiah S. Premenstrual syndrome. In: Blackwell RE, editor. Women’s medicine. New York: Blackwell Science Publishing; 2002. p. 503–17.Google Scholar
  27. 27.
    Schmidt PJ, Nieman LK, Grover GN, Muller KL, Merriam GR, Rubinow DR. Lack of effect of induced menses on symptoms in women with premenstrual syndrome. N Engl J Med. 1991;324(17):1174–9.CrossRefGoogle Scholar
  28. 28.
    Yonkers KA, Kornstein SG, Gueorguieva R, Merry B, Van Steenburgh K, Altemus M. Symptom-onset dosing of sertraline for the treatment of premenstrual dysphoric disorder: a randomized clinical trial. JAMA Psychiat. 2015;72(10):1037–44.CrossRefGoogle Scholar
  29. 29.
    Rickels K, Freeman E, Sondheimer S. Buspirone in treatment of premenstrual syndrome. Lancet. 1989;1(8641):777.CrossRefGoogle Scholar
  30. 30.
    Freeman EW. Luteal phase administration of agents for the treatment of premenstrual dysphoric disorder. CNS Drugs. 2004;18(7):453–68.CrossRefGoogle Scholar
  31. 31.
    Mitchell AA, Gilboa SM, Werler MM, Kelley KE, Louik C, Hernández-Díaz S. Medication use during pregnancy, with particular focus on prescription drugs: 1976–2008. Am J Obstet Gynecol. n.d.;205(1):51.e51–51.e58.CrossRefGoogle Scholar
  32. 32.
    Koren G, Sakaguchi S, Klieger C, Kazmin A, Osadchy A, Yazdani-Brojeni P, Matok I. Toward improved pregnancy labelling. J Popul Ther Clin Pharmacol. 2010;17(3):e349–57.PubMedGoogle Scholar
  33. 33.
    US Food & Drug Administration. FDA issues final rule on changes to pregnancy and lactation labeling information for prescription drug and biological products [press release]. Retrieved from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm425317.htm. 2014
  34. 34.
    Ryan D, Milis L, Misri N. Depression during pregnancy. Can Fam Physician. 2005;51(8):1087–93.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Gentile S. Untreated depression during pregnancy: short- and long-term effects in offspring. A systematic review. Neuroscience. 2017;242:154–166.CrossRefGoogle Scholar
  36. 36.
    Cohen LS, Altshuler LL, Harlow BL, Nonacs R, Newport DJ, Viguera AC, Stowe ZN. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA. 2006;295(5):499–507.CrossRefGoogle Scholar
  37. 37.
    Yonkers KA, Blackwell KA, Glover J, Forray A. Antidepressant use in pregnant and postpartum women. Annu Rev Clin Psychol. 2014;10(1):369–92.CrossRefGoogle Scholar
  38. 38.
    Wesseloo R, Kamperman AM, Munk-Olsen T, Pop VJ, Kushner SA, Bergink V. Risk of postpartum relapse in bipolar disorder and postpartum psychosis: a systematic review and meta-analysis. Am J Psychiatry. 2016;173(2):117–27.CrossRefGoogle Scholar
  39. 39.
    Viguera AC, Whitfield T, Baldessarini RJ, Newport DJ, Stowe Z, Reminick A, Cohen LS. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry. 2007;164(12):1817–24. quiz 1923CrossRefGoogle Scholar
  40. 40.
    Cohen LS, Friedman JM, Jefferson JW, Johnson EM, Weiner ML. A reevaluation of risk of in utero exposure to lithium. JAMA. 1994;271(2):146–50.CrossRefGoogle Scholar
  41. 41.
    Epstein RA, Moore KM, Bobo WV. Treatment of bipolar disorders during pregnancy: maternal and fetal safety and challenges. Drug Healthc Patient Saf. 2015;7:7–29.PubMedGoogle Scholar
  42. 42.
    Yonkers KA, Wisner KL, Stowe Z, Leibenluft E, Cohen L, Miller L, Altshuler L. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry. 2004;161(4):608–20.CrossRefGoogle Scholar
  43. 43.
    Mines D, Tennis P, Curkendall SM, Li DK, Peterson C, Andrews EB, Chan KA. Topiramate use in pregnancy and the birth prevalence of oral clefts. Pharmacoepidemiol Drug Saf. 2014;23(10):1017–25.CrossRefGoogle Scholar
  44. 44.
    US Food & Drug Administration. Suicidal behavior and ideation and antiepileptic drugs. Retrieved from http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm100190.htm. 2009.
  45. 45.
    Dolovich LR, Addis A, Vaillancourt JM, Power JD, Koren G, Einarson TR. Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies. BMJ. 1998;317(7162):839–43.CrossRefGoogle Scholar
  46. 46.
    Huybrechts KF, Hernandez-Diaz S, Patorno E, Desai RJ, Mogun H, Dejene SZ, Bateman BT. Antipsychotic use in pregnancy and the risk for congenital malformations. JAMA Psychiat. 2016;73(9):938–46.CrossRefGoogle Scholar
  47. 47.
    Galbally M, Snellen M, Power J. Antipsychotic drugs in pregnancy: a review of their maternal and fetal effects. Ther Adv Drug Saf. 2014;5(2):100–9.CrossRefGoogle Scholar
  48. 48.
    Sadowski A, Todorow M, Yazdani Brojeni P, Koren G, Nulman I. Pregnancy outcomes following maternal exposure to second-generation antipsychotics given with other psychotropic drugs: a cohort study. BMJ Open. 2013;3(7) pii: e003062. https://doi.org/10.1136/bmjopen-2013-003062.
  49. 49.
    US Food & Drug Administration. FDA drug safety communication: antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns [press release]. Retrieved from http://www.fda.gov/Drugs/DrugSafety/ucm243903.htm. 2011.
  50. 50.
    Heron J, O’Connor TG, Evans J, Golding J, Glover V. The course of anxiety and depression through pregnancy and the postpartum in a community sample. J Affect Disord. 2004;80(1):65–73.CrossRefGoogle Scholar
  51. 51.
    Ross LE, McLean LM. Anxiety disorders during pregnancy and the postpartum period: a systematic review. J Clin Psychiatry. 2006;67(8):1285–98.CrossRefGoogle Scholar
  52. 52.
    Sui G, Pan B, Liu G, Liu G, Wang L. The long-term effects of maternal postnatal depression on a child’s intelligence quotient: a meta-analysis of prospective cohort studies based on 974 cases. J Clin Psychiatry. 2016;77:e1474–82.CrossRefGoogle Scholar
  53. 53.
    Halbreich U, Karkun S. Cross-cultural and social diversity of prevalence of postpartum depression and depressive symptoms. J Affect Disord. 2006;91(2):97–111.CrossRefGoogle Scholar
  54. 54.
    Berle JØ, Spigset O. Antidepressant use during breastfeeding. Curr Womens Health Rev. 2011;7(1):28–34.CrossRefGoogle Scholar
  55. 55.
    O’Hara MW, Stuart S, Gorman LL, Wenzel A. Efficacy of interpersonal psychotherapy for postpartum depression. Arch Gen Psychiatry. 2000;57(11):1039–45.CrossRefGoogle Scholar
  56. 56.
    Jones I, Chandra PS, Dazzan P, Howard LM. Bipolar disorder, affective psychosis, and schizophrenia in pregnancy and the post-partum period. Lancet. 2014;384(9956):1789–99.CrossRefGoogle Scholar
  57. 57.
    Viguera AC, Nonacs R, Cohen LS, Tondo L, Murray A, Baldessarini RJ. Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. Am J Psychiatry. 2000;157(2):179–84.CrossRefGoogle Scholar
  58. 58.
    Bergink V, Rasgon N, Wisner KL. Postpartum psychosis: madness, mania, and melancholia in motherhood. Am J Psychiatry. 2016;173(12):1179–88.CrossRefGoogle Scholar
  59. 59.
    Sit D, Rothschild AJ, Wisner KL. A review of postpartum psychosis. J Womens Health (Larchmt). 2006;15(4):352–68.CrossRefGoogle Scholar
  60. 60.
    American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108(3):776–89.CrossRefGoogle Scholar
  61. 61.
    Fortinguerra F, Clavenna A, Bonati M. Psychotropic drug use during breastfeeding: a review of the evidence. Pediatrics. 2009;124(4):e547–56.CrossRefGoogle Scholar
  62. 62.
    Seritan AL, Iosif AM, Park JH, DeatherageHand D, Sweet RL, Gold EB. Self-reported anxiety, depressive, and vasomotor symptoms: a study of perimenopausal women presenting to a specialized midlife assessment center. Menopause. 2010;17(2):410–5.CrossRefGoogle Scholar
  63. 63.
    Parry BL. Perimenopausal depression. Am J Psychiatry. 2008;165(1):23–7.CrossRefGoogle Scholar
  64. 64.
    Parry BL. Optimal management of perimenopausal depression. Int J Womens Health. 2010;2:143–51.CrossRefGoogle Scholar
  65. 65.
    Chandraiah S, Richter H, Holley R. Relationship of reproductive cycle-associated and non-reproductive cycle-associated psychological problems in women. Int J Fertil Womens Med. 2005;51(1):33–7.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Quillen College of Medicine, Department of Psychiatry and Behavioral SciencesEast Tennessee State UniversityJohnson CityUSA

Personalised recommendations